# CONTENTS

List of Abbreviations......................................................................................(i)
List of Figures................................................................................................(iii)
List of Tables...................................................................................................(v)

## 1. INTRODUCTION/REVIEW OF LITERATURE

1.1 Smoking Prevalence..................................................................................1
1.2 Second Hand Smoke (SHS) or Passive Smoking.................................2
1.3 Second Hand Smoke (SHS) or Passive Smoking and Oxidative Stress..3
1.4 Smoking and CVD....................................................................................4
1.5 Evidence of Smoking-Induced CVD.......................................................5
1.6 Pathophysiology of Smoking and CVD................................................5
1.7 Atherosclerosis.......................................................................................6
1.8 Oxidative Stress in Human Erythrocytes.............................................7
    1.8.1 Formation of ROS from molecular oxygen.................................8
    1.8.2 Iron redox status and oxidative stress in erythrocytes..............11
    1.8.3 Cellular antioxidant defense systems against ROS.................11
        1.8.3.1 Enzymatic antioxidants..................................................12
        1.8.3.2 Nonenzymatic antioxidants..........................................14
        1.8.3.3 Exogenous antioxidants................................................15
1.9 Atherogenic Properties of Oxidized LDL and Small Dense LDL........16
1.10 Management of Cigarette Smoke-Induced Oxidative Stress and Hyperlipidemia/Dyslipidemia..........................................................20
1.11 Objectives of the Present Study...........................................................26

## 2. EXPERIMENTAL

2.1 Materials....................................................................................................33
    2.1.1 Chemicals.....................................................................................33
    2.1.2 Animals/Exposure to Cigarette Smoke and Treatments..............35
2.2 Methods....................................................................................................36
    2.2.1 Preparation of Methanol and Essential Oil Extracts from *Nigella sativa* (NS) Seeds.................................................................36
        2.2.1.1 Extraction of ME................................................................36
        2.2.1.2 Extraction of EO...............................................................36
2.2.2 Analytical Procedures.

2.2.2.1 Collection of blood and preparation of erythrocytes/membranes.

2.2.2.2 Preparation of liver homogenate and post-mitochondrial supernatant.

2.2.2.3 Determination of 2, 2-Diphenyl-1-Picryl Hydrazyl radical (DPPH•) scavenging activity (antioxidant capacity) of NS seed and its ME, EO fraction; pure thymoquinone (TQ) and pure limonene (LMN).

2.2.2.4 Determination of plasma triglycerides.

2.2.2.5 Fractionation of plasma lipoproteins.

2.2.2.6 Determination of plasma cholesterol.

2.2.2.7 Measurement of ex vivo and in vitro Cu²⁺- mediated susceptibility of LDL, sd-LDL and lb-LDL to oxidation.

2.2.2.8 Ferric reducing activity (FRAP assay).

2.2.2.9 Assay of plasma arylesterase antioxidant enzyme activity.

2.2.2.10 Measurement of malondialdehyde release from intact erythrocytes.

2.2.2.11 Determination of malondialdehyde in erythrocytes.

2.2.2.12 Assay of total and magnesium-dependent ATPase activities in erythrocyte membrane.

2.2.2.13 Estimation of lipid peroxides in plasma and liver homogenate.

2.2.2.14 Assay of HMG-CoA reductase activity in liver homogenate.

2.2.2.15 Activities of antioxidant enzymes.

2.2.2.15.1 Determination of catalase activity in erythrocytes and liver.

2.2.2.15.2 Determination of superoxide dismutase activity in erythrocytes and liver.

2.2.2.15.3 Determination of glutathione peroxidase activity in erythrocytes and liver.

2.2.2.15.4 Assay of glutathione reductase activity in erythrocytes and liver.

2.2.2.15.5 Determination of glutathione-S-transferase activity in liver.

2.2.2.16 Determination of GSH, GSSG and membrane-bound-SH contents in erythrocyte.
3. RESULTS

3.1 Comparison of Scavenging Activities of Methanol Extract (ME) and Essential Oil (EO) Extract of Nigella sativa (NS) Seed Powder; Pure Thymoquinone (TQ) and pure Limonene (LMN) against 2, 2-Diphenyl-1-Picryl Hydrazyl (DPPH) radical.

3.2 Average Body Weight, Food Intake and Liver Weight.

3.3 Impact of ME and EO Extract from NS Seed Powder; Pure TQ and pure LMN on Plasma Antioxidant Status and Lipid Peroxidation Status in Plasma, Erythrocyte and Liver in Cigarette Smoke (CS) Exposed Rats Treated for 30 Days.

3.3.1 Impact on plasma FRAP, arylesterase antioxidant enzyme activity and lipid peroxidation products.

3.3.2 Effect on membrane lipid peroxidation in erythrocytes.

3.3.3 Impact on liver lipid peroxidation products.

3.4 Modulatory Effects of ME, EO, Pure TQ and pure LMN on Antioxidant Defense System and Erythrocyte Membrane Bound ATPase Activity in CS Exposed Rats.

3.4.1 Effect on erythrocyte catalase (CAT), superoxide dismutase (SOD), glutathione peroxidase (Gpx) and glutathione reductase (Gred) activities.

3.4.2 Effect on erythrocyte membrane bound total, Mg++- and Na+, K+-dependent ATPase activities.

3.4.3 In vitro protective effect of pure TQ on tert-butyl hydroperoxide (t-BHP)-induced membrane bound total, Mg++- and Na+, K+-dependent ATPase activities in pooled erythrocytes from N-C and CS-C rats.

3.4.4 In vitro protective effect of ME, EO extract, pure TQ and pure LMN on t-BHP-induced changes in GSH content of pooled erythrocytes from N-C, CS-C; CS-ME, CS-EO, CS-TQ and CS-LMN rats.
3.4.5 In vitro protective effect of pure TQ on free, membrane bound sulfhydryl contents and oxidized glutathione (GSSG) in t-BHP stressed-erythrocytes from normal (N-C) and CS exposed (CS-C) rats.

3.4.6 Impact on the in vivo modulation of liver catalase (CAT), superoxide dismutase (SOD), glutathione peroxidase (Gpx), glutathione reductase (Gred) and glutathione-S-transferase (GST) activities.

3.5 Effect on Hepatic Total, Free and Membrane-Bound Sulfhydryl Contents, Oxidized Glutathione (GSSG) and GSSG:GSH ratio.

3.6 Impact of ME and EO Extract from NS Seed Powder; Pure TQ and pure LMN on Plasma Lipids, Plasma Lipoprotein Lipids and Hepatic HMG-CoA Reductase Activity in CS Exposed Rats Treated for 30 Days.

3.6.1 Effect on plasma and lipoprotein lipids.

3.6.2 Effect on enzymatic activity of hepatic HMG-CoA reductase.

3.6.3 Effect on plasma LDL, small dense LDL and large buoyant LDL subfractions.

3.6.4 Effect on HDL-C/LDL-C, HDL-C/TC and HDL-C/TG ratios.

3.7 Ex Vivo and In Vitro Cu²⁺-Mediated Oxidation of LDL, Sd-LDL and Lb-LDL in CS Exposed Rats Treated with ME, EO, Pure TQ or pure LMN.

3.7.1 Antioxidant effect on basal and maximal levels of CD formation and lag time in LDL, sd-LDL and lb-LDL.

3.7.2 Antioxidant impact on basal and maximal levels of MDA in LDL, sd-LDL and lb-LDL.

4. DISCUSSION

5. SUMMARY

6. BIBLIOGRAPHY